How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer-Reference-Cited by-同舟云学术

How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

Published:2019-06 Issue:6 Volume:30 Page:884-896
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Peters S.,Reck M.,Smit E.F.,Mok T.,Hellmann M.D.

Funder

Merck Sharp & Dohme Corp.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz109/28572661/mdz109.pdf

Reference100 articles.

1. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Novello;Ann Oncol,2016

2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines). Non-Small Cell Lung Cancer, Version 8, 2017; https://www.nccn.org (18 July 2017, date last accessed).

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

5. A systematic review of targeted agents for non-small cell lung cancer;Vestergaard;Acta Oncol,2018

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort;Translational Oncology;2024-09

2. The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study;Cancer Management and Research;2024-08

3. Thoracic sarcopenia was a poor prognostic predictor in patients receiving immunotherapy retain-->for advanced non-small-cell retain-->lung cancer;Academic Radiology;2024-08

4. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer;PLOS ONE;2024-07-31

5. Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies;Clinical Lung Cancer;2024-07